Answers are grounded in this paper and cite their sources.
Phase 1 trial assesses safety and pharmacokinetics of ART5803 in healthy volunteers, suggesting potential therapeutic effects.
To assess the safety and pharmacokinetic profile of ART5803, a therapeutic one-armed antibody designed to block the pathogenicity of anti-NMDA receptor (NMDAR) autoantibodies in patients with anti-NMDAR encephalitis (ANRE), in healthy volunteers.
No takes yet. Share an insight, caveat, or question.
Gokhale et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: